$25.110
+0.490 (+1.95%)收盤時
AVLN 同業比較
In the context of the broader market, AVLN competes directly with industry leaders such as HROW and IMTX. With a market capitalization of $1.26B, it holds a leading position in the sector. When comparing efficiency, AVLN's gross margin of N/A stands against HROW's 71.27% and IMTX's 100.00%. Such benchmarking helps identify whether Avalyn Pharma Inc is trading at a premium or discount relative to its financial performance.
Avalyn Pharma Inc 財務表現
Avalyn Pharma has reported a net income loss of -28.9 million in Q2 2026, with an EPS of -0.98. Despite these losses, the company has a strong current ratio of 33.12, indicating good short-term financial health.
Financials
FY2026Q2
YoY:
+43.68%
-31.29M
Operating Profit
FY2026Q2
YoY:
+43.31%
-28.93M
Net Income after Tax
FY2026Q2
YoY:
+104.17%
-0.98
EPS - Diluted
FY2026Q2
YoY:
+27.29%
-26.34M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。